BSE · 539680
Ganga Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹3 Cr with net profit ₹0 Cr — a 2.57% net margin, versus 1.57% the period before.
Shareholding
As of 2026-03-31
- Promoter50.91%
- Public49.09%
365 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.56× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #42 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 423.85 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,264 Cr | 326.41 | 19.62 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.51 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Ganga Pharmaceuticals Limited(this company) | ₹7 Cr | 70.59 | 0.85 | 1.22% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashGanga Pharmaceuticals Limited has a market capitalization of Rs 7 Cr. The company's PE ratio is 70.59, and it has a book value of Rs 14.06. Its EPS stands at Rs 0.17, with a ROE of 122.1% and ROCE of 2.79%. The debt-to-equity ratio is 0.2. The company generated revenue of Rs 3.07 Cr. Promoter holding is 50.91%, with public holding at 49.09%. The company faces surveillance under GSM 0.
Positives
- +The Return on Equity (ROE) is high at 122.1%.
- +Net profit has increased from Rs 0.02 Cr in March 2021 to Rs 0.08 Cr in March 2025.
- +The debt-to-equity ratio is low at 0.2.
Negatives
- −The profit margin is 0%, indicating no reported profit as a percentage of revenue.
- −The Return on Capital Employed (ROCE) is low at 2.79%.
- −The company is under 'GSM · GSM 0' surveillance.
- −The company has not disclosed quarterly results.
Financial Performance
Ganga Pharmaceuticals Limited reported revenue of Rs 3.07 Cr in the latest period. Net profit increased from Rs 0.02 Cr in March 2021 to Rs 0.08 Cr in March 2025. Over the same period, EPS grew from Rs 0.05 to Rs 0.12. The company's EBITDA also saw an increase from Rs 0.23 Cr in March 2021 to Rs 0.27 Cr in March 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 122.1%, while its Return on Capital Employed (ROCE) is 2.79%. The profit margin for the company is 0%. The EPS for the latest period is Rs 0.17. While ROE is high, the ROCE is significantly lower.
Balance Sheet
Ganga Pharmaceuticals Limited has a debt-to-equity ratio of 0.2, indicating a relatively low level of debt compared to equity. The book value per share is Rs 14.06. No dividend yield is reported for the company.
Ownership & Pledges
There are no shares pledged by the promoters. The number of shareholders is 365. There has been no reported holding by DII or FII.
Regulatory & Surveillance
Ganga Pharmaceuticals Limited is currently under surveillance with a 'GSM · GSM 0' categorization, indicating it is subject to graded surveillance measures. There is no information provided about new pledge activity in recent financial periods.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Ganga Pharmaceuticals Limitedshare price & fundamentals